Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Boehringer, Astellas to Extend Sales Pact for Micardis Family of Products to March 2020
November 1, 2017
- Sumitomo Dainippon Beats 1st Half Guidance, Ups Full-Year Outlook
October 31, 2017
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
- JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
October 30, 2017
- JCR Starts Development of Another BBB-Penetrating Drug for Hurler Syndrome
October 30, 2017
- Mogamulizumab Accepted for Review in Europe: Kyowa Kirin
October 30, 2017
- JSR Grabs License to Gut Bacteria Research Outcome by Keio Univ./Univ. of Tokyo, I/O Drug Discovery Eyed
October 30, 2017
- Crestor Generics of Sawai, Pfizer to Get Listed with Full Indications
October 27, 2017
- Eisai Ups Profit Estimates for April-September
October 27, 2017
- Ono Lifts Half-Year Guidance on Opdivo Boon
October 27, 2017
- Mitsubishi Tanabe Withdraws Petitions for Injunction against 3 Generic Makers Over Talion Patent Infringement
October 27, 2017
- Fujifilm Invests in Japan Biomedical to Boost Regenerative Medicine Business
October 27, 2017
- Novartis Seeks SJIA Indication for Ilaris in Japan
October 26, 2017
- Shionogi’s Sakigake-Designated Flu Med Filed in Japan
October 26, 2017
- Parmodia, Canalia Climb GP Recollection Ranking in August: Anterio
October 25, 2017
- Sumitomo Dainippon Joins Forces with Nobel Laureate to Tackle AMR Infections
October 25, 2017
- Expanded Aducanumab Collaboration Will Be a Plus for Other Alzheimer’s Pipelines: Eisai CEO
October 25, 2017
- Mitsubishi Tanabe Trims Forecast on Sluggish Invokana Royalties
October 25, 2017
- BMS, Pfizer Launch Japan Clinical Research for Atrial Fibrillation Detection
October 24, 2017
- Eisai Opts to Codevelop Biogen’s Aducanumab; New MS Copromotion Scheme Sealed
October 24, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…